One of the many unanswered scientific questions about COVID-19 is whether it is seasonal like the flu – waning in warm summer months then resurging in the fall and winter. Now scientists at Lawrence Berkeley National Laboratory are launching a project to apply machine-learning methods to a plethora of health and environmental datasets, combined with high-resolution climate models and seasonal forecasts, to tease out the answer.
An international scientific team has discovered a neutralizing antibody, derived from the blood of a SARS survivor, that inhibits the closely related COVID-19-causing coronavirus. In a paper published this week in Nature, the scientists note that the antibody is already on an accelerated development path toward clinical trials.
As society prepares to reopen indoor spaces and ease back into some sense of normalcy during the COVID-19 pandemic, a team of researchers at Berkeley Lab is launching a study of the risk of airborne transmission of viruses within buildings and how to mitigate those risks.
Scientists from Pacific Northwest and Lawrence Berkeley National Laboratories showed that both dietary and supplementary sources of a common gut microbe or its main chemical product, lactic acid, led to better memory performance in mice.
Berkeley Lab’s Advanced Light Source X-ray facility has been recalled to action to support research related to COVID-19, the coronavirus disease that has already infected about 2 million people around the world.
One strategy to make biofuels more competitive is to make plants do some of the work themselves. Scientists can engineer plants to produce valuable chemical compounds, or bioproducts, as they grow. Then the bioproducts can be extracted from the plant and the remaining plant material can be converted into fuel. But one important part of this strategy has remained unclear — exactly how much of a particular bioproduct would plants need to make in order to make the process economically feasible?
Distinguished senior scientist Mina Bissell is one of five recipients of the 2020 Canada Gairdner International Award – an annual honor given to scientists who have contributed to transformative human health research.
A new material design has put the long-sought idea of artificial photosynthesis within reach.
Biomanufacturing – harnessing biological processes in cells and microbes to design and manufacture products – is revolutionizing how we make everything from futuristic consumer goods to sustainable fuels to breakthrough medicines. Every biomanufactured product can be traced back to discoveries in the lab, but translating that science into a real-world product can be tricky. Berkeley Lab is helping to move great ideas, like outdoor gear made from algae oil, from conception to commercialization.
An investigational cancer drug that targets tumors caused by mutations in the KRAS gene will be evaluated in phase 2 clinical trials, following promising safety and efficacy results in preliminary human studies and excellent results in animal studies. The drug, developed by Amgen and currently referred to as AMG 510, is the first therapy to reach clinical